Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
NCT ID: NCT00046254
Last Updated: 2012-05-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
2127 participants
INTERVENTIONAL
2002-02-28
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
NCT00439647
Zoledronate Early to Hip Fracture Patients - Safe and Effective?
NCT05025293
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
NCT00097825
Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
NCT01267279
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
NCT05405894
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zoledronic Acid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have a recent hip fracture repair in the past 90 days
* Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture
Exclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama Hospital
Birmingham, Alabama, United States
Osteoporosis Diagnostic Center
Eureka, California, United States
Sharp Grossmont Hosptial
La Mesa, California, United States
The Permanente Group
Santa Rosa, California, United States
Radiant Research Lake Worth
Lake Worth, Florida, United States
Atlanta Resarch Center
Decatur, Georgia, United States
United Osteoporosis Center Health Services
Gainesville, Georgia, United States
Galesburg Orthopedic Services LTD
Galesburg, Illinois, United States
Illinois Bone and Joint Institute
Morton Grove, Illinois, United States
Mercy Arthritis and Osteoporosis Center
Des Moines, Iowa, United States
Maine Medical Center Research Institute
Portland, Maine, United States
University of Maryland School of Medicine
Baltimore, Maryland, United States
Wayne State University, Div. of Endocrinology
Detroit, Michigan, United States
Health East Osteoporosis Service
Woodbury, Minnesota, United States
Highland Hospital
Rochester, New York, United States
University of North Carolina Hospital
Chapel Hill, North Carolina, United States
Duke University Health System
Durham, North Carolina, United States
University Orthopaedics
Canfield, Ohio, United States
Ohio State University
Columbus, Ohio, United States
University of Pennsylvania Health System-Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
Saint Joseph Medical Center
West Reading, Pennsylvania, United States
Saint Josephs
Warwick, Rhode Island, United States
Palmetto Richland Memorial Hospital
Columbia, South Carolina, United States
Seton Medical Center
Austin, Texas, United States
St. Luke's Episcopal Hospital
Houston, Texas, United States
Danville Regional Medical Center
Danville, Virginia, United States
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Novartis
Nuremberg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Magaziner JS, Orwig DL, Lyles KW, Nordsletten L, Boonen S, Adachi JD, Recknor C, Colon-Emeric CS, Mesenbrink P, Bucci-Rechtweg C, Su G, Johnson R, Pieper CF. Subgroup variations in bone mineral density response to zoledronic acid after hip fracture. J Bone Miner Res. 2014 Dec;29(12):2545-51. doi: 10.1002/jbmr.2283.
Prieto-Alhambra D, Judge A, Arden NK, Cooper C, Lyles KW, Javaid MK. Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial. Osteoporos Int. 2014 Jan;25(1):77-83. doi: 10.1007/s00198-013-2420-8. Epub 2013 Jun 28.
Adachi JD, Lyles KW, Colon-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int. 2011 Sep;22(9):2539-49. doi: 10.1007/s00198-010-1514-9. Epub 2011 Jan 20.
Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010 Nov;141(11):1365-70. doi: 10.14219/jada.archive.2010.0082.
Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov 1;357(18):1799-809. doi: 10.1056/NEJMoa074941. Epub 2007 Sep 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CZOL446H2310
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.